Zaragozic acid A trisodium salt
SIGMA/Z2626 - ≥95% (HPLC), microbial
Synonym: L-694,599; Squalestatin
CAS Number: 144541-82-2
Empirical Formula (Hill Notation): C35H43O14Na3
Molecular Weight: 756.68
MDL Number: MFCD03788025
Linear Formula: C35H43O14Na3
Product Type: Chemical
| assay | ≥95% (HPLC) |
| biological source | microbial |
| form | lyophilized powder |
| Quality Level | 200  |
| shipped in | wet ice |
| solubility | DMSO: 9.80-10.20 mg/mL, clear, colorless to faintly yellow |
| storage temp. | −20°C |
| Application: | Zaragozic acid A trisodium salt has been used as: • a component of serum-free medium for human embryonic kidney cells in a wound scratch assay to test its effect on wound healing • a farnesyl-diphosphate farnesyltransferase 1 (FDFT1) or squalene synthase inhibitor in stromal cells • a cholesterol synthesis inhibitor in T cells |
| Biochem/physiol Actions: | Potent inhibitor, in vivo and in vitro, of mammalian, fungal and Saccharomyces cervisiae squalene synthase. Squalene synthase is the first committed enzyme in sterol synthesis, catalyzing the reductive condensation of farnesyl pyrophosphate to form squalene. As a squalene synthase inhibitor, zaragozic acid produces lower plasma cholesterol levels in primates. Treatment of rats with zaragozic acid A caused an increase in hepatic low density lipoprotein (LDL) receptor mRNA levels. |
| Legal Information: | Manufactured and sold under a restricted license from Merck & Co., Inc., Kenilworth, NJ, U.S. |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥95% (HPLC) |
| Storage Temp. | −20°C |
| UNSPSC | 12352200 |